Mannkind Corporation - $MNKD STOCK NEWS

MannKind (Nasdaq: MNKD) will host a conference call to discuss its 2024 first quarter financial results on May 8, 2024. Interested parties can listen live on the Company's website.

MannKind (Nasdaq: MNKD) has announced the initiation of a Phase 1 study for nintedanib DPI (MNKD-201) targeting pulmonary fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). This study will assess safety, tolerability, and pharmacokinetics in healthy volunteers, with enrollment expected to commence in June 2024. The company aims to provide potential treatment options for patients with serious lung diseases, following their ongoing Phase 3 study of Clofazimine Inhalation Suspension for nontuberculous mycobacterial (NTM) lung diseases.

MannKind has received clearance from the U.S. FDA to start a Phase 3 study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease. The IND clearance enables the company to initiate a Phase 3 trial to evaluate the efficacy and safety of Clofazimine Inhalation Suspension in treating refractory NTM lung disease caused by Mycobacterium Avium Complex (MAC). This study, identified as ICoN-1, is set to begin by the end of the second quarter of 2024 in the U.S. and later in the second half of 2024 internationally. NTM lung disease is becoming increasingly prevalent worldwide, with significant impact on patients' lives and rising annual growth rates.

MannKind (MNKD) has repaid its credit and security agreement with MidCap Financial Trust and convertible note issued to Mann Group in full, reducing total debt by approximately $41.8 million. The repayment includes $31.6 million to MidCap Financial Trust and exchange for 1.5 million shares of common stock and $8.9 million to Mann Group CEO Michael Castagna highlighted the elimination of expensive debt and undervaluation of the stock.

MannKind announces Steven B. Binder's retirement as CFO and the appointment of Christopher Prentiss as the new CFO. Binder will transition to Executive Vice President, Special Projects until the end of 2024. Prentiss brings over 20 years of financial leadership experience in the biopharma industry, having served in various finance positions in both private and public companies.

MannKind Corporation announces promising results from the INHALE-3 Phase 4 clinical trial, showing a significant reduction in post-meal hyperglycemia and glucose excursions with inhaled insulin compared to standard care.

MannKind Corporation (Nasdaq: MNKD) to present new clinical data from the INHALE-3 study at the ATTD Conference. Dr. Hirsch will discuss results of switching from MDI or insulin pumps to inhaled insulin (Afrezza®). The study focuses on post-prandial glucose levels, hypoglycemia frequency, and mealtime control in T1D patients.

MannKind Corporation (MNKD) announced its participation in upcoming conferences to showcase its inhaled therapeutic products. The company will be presenting at Leerink Partners Global Biopharma Conference 2024 and Oppenheimer 34th Annual Healthcare MedTech & Services Conference. Interested parties can access the live webcast and replay on the company's website.

MannKind Corporation reports impressive financial results for Q4 2023 and full year 2023 with total revenues of $199M, net income of $1M, and cash position of $302M. Positive revenue growth driven by Afrezza and collaborations. Clinical trials progressing well with upcoming data read-outs and FDA submissions.